+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Bone density in proton pump inhibitors users: a prospective study



Bone density in proton pump inhibitors users: a prospective study



Rheumatology International 33(9): 2255-2260



Patients with gastroesophageal reflux disease (GERD) receive long-term therapy with proton pump inhibitor (PPI) agents. Several studies have recently been published suggesting that treatment with PPI may cause bone fractures, although the number of prospective studies in this regard is limited. The aim of this study is to prospectively investigate the effect of PPIs on bone density. Between March 2009 and January 2011, 114 GERD patients (18-56 years) and 110 healthy controls were included in the present study. Bone mineral densitometry (BMD) by using dual-energy X-ray absorptiometry was assessed at lumbar spine and femur neck. BMD measurements were performed on all subjects at the beginning of the study. The patients were divided according to three drugs by their treatment with esomeprazole, lansoprazole, or pantoprazole. The study group was followed for at least 6 months on PPI therapy, and then BMD measurements were repeated. The mean duration of treatment with PPIs was 8.5 ± 2.3 months. In patients receiving PPIs, the mean reduction in total vertebra T score following treatment compared to pre-treatment values was 00.23 ± 0.42 units (95 % CI 0.15-0.30) (p < 0.01), while the mean reduction in the femur T score was 0.10 ± 0.40 units (95 % CI 0.03-0.18) (p = 0.03). Reduction following treatment in L4 and total vertebra T scores of lansoprazole group was significantly higher than of pantoprazole group (p = 0.04). Reduction in femur T score of esomeprazole group was higher than of lansoprazole group and pantroprazole group, but it is not statistically significant. Treatment with a PPI results in a significant reduction in bone density. Close monitoring is beneficial for patients who are to receive long-term treatment with PPI.

(PDF emailed within 0-6 h: $19.90)

Accession: 036790550

Download citation: RISBibTeXText

PMID: 23455632

DOI: 10.1007/s00296-013-2709-0


Related references

Proton pump inhibitors use and change in bone mineral density. International Journal of Rheumatic Diseases 19(9): 864-868, 2017

Comparing Bone Structure and Bone Metabolism Between Long-Term Proton Pump Inhibitor Users and Non-Users. Gastroenterology 148(4): S-153, 2015

Mo1082 The Effect of Three Months use of Proton Pump Inhibitors on Bone Mineral Density, Bone Markers and Calcium Metabolism in Men With Gastroesophageal Reflux Disease. Gastroenterology 142(5): S-590, 2012

Effect of long-term proton pump inhibitors on bone mineral density. La Tunisie Medicale 96(3): 193-197, 2018

Fracture risk and bone mineral density reduction associated with proton pump inhibitors. PharmacoTherapy 32(1): 67-79, 2012

Correlation of Bone Mineral Density Scores and Proton Pump Inhibitors Use in the Elderly. Current Rheumatology Reviews 12(2): 162-166, 2017

Long-term therapy with proton pump inhibitors is associated with decreased bone density. Medical Hypotheses 72(5): 608-609, 2009

Use of proton pump inhibitors is associated with lower trabecular bone density in older individuals. Bone 57(2): 437-442, 2014

A comparison of the gut microbiome between long-term users and non-users of proton pump inhibitors. Alimentary Pharmacology and Therapeutics 43(9): 974-984, 2016

Efficacy and safety of hangeshashinto for treatment of GERD refractory to proton pump inhibitors : Usual dose proton pump inhibitors plus hangeshashinto versus double-dose proton pump inhibitors: randomized, multicenter open label exploratory study. Journal of Gastroenterology 2019, 2019

Proton pump inhibitors do not induce change in bone mineral density in a long-term observational study. Evidence-Based Medicine 18(5): 192-193, 2014

Efficacy of alfacalcidol and alendronate on lumbar bone mineral density in osteoporotic patients using proton pump inhibitors. Biomedical Reports 5(2): 165-170, 2016

Bone mineral density changes among women initiating proton pump inhibitors or H2 receptor antagonists: a SWAN cohort study. Journal of Bone and Mineral Research 30(2): 232-239, 2016

Proton pump inhibitors have no measurable effect on calcium and bone metabolism in healthy young males: a prospective matched controlled study. Metabolism: Clinical and Experimental 62(4): 518-526, 2013

W1060 Hospitalizations for Gastrointestinal Events Among Users of Cox-2 Inhibitors Compared with Traditional Non-Steroidal Anti-Inflammatory Drugs with Proton-Pump Inhibitors. Gastroenterology 134(4): A-625, 2008